更新于：2024-12-28
Zalutumumab
扎鲁木单抗
更新于：2024-12-28
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
序列信息
Sequence Code 143885L
来源: *****
Sequence Code 9060792H
来源: *****
关联
16
项与 扎鲁木单抗 相关的临床试验An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN - Zalutumumab PK in SCCHN
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy
100 项与 扎鲁木单抗 相关的临床结果
登录后查看更多信息
100 项与 扎鲁木单抗 相关的转化医学
登录后查看更多信息
100 项与 扎鲁木单抗 相关的专利（医药）
登录后查看更多信息
57
项与 扎鲁木单抗 相关的文献（医药）2024-09-04MOLECULAR CANCER THERAPEUTICS
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0
Article
作者: Olofsen, Patricia A. ; Leusen, Jeanette H.W. ; Valerius, Thomas ; Peipp, Matthias ; Verdonschot, Meggy E.L. ; Tsioumpekou, Maria ; van der Peet, Ida C. ; Hendriks, Ilona S.T. ; Nederend, Maaike ; Passchier, Elsemieke M. ; Klomp, Sharon A. ; Jansen, J.H. Marco ; Chan, Chilam
Abstract:
EGFR plays an essential role in cellular signaling pathways that regulate cell growth, proliferation, and survival and is often dysregulated in cancer. Several monoclonal IgG antibodies have been clinically tested over the years, which exert their function via blocking the ligand binding domain (thereby inhibiting downstream signaling) and inducing Fc-related effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). However, these IgG antibodies do not optimally recruit neutrophils, which are the most abundant white blood cell population in humans. Therefore, we reformatted six therapeutic EGFR antibodies (cetuximab, panitumumab, nimotuzumab, necitumumab, zalutumumab, and matuzumab) into the IgA3.0 format, which is an IgA2 isotype adapted for clinical application. Reformatting these antibodies preserved Fab-mediated functions such as EGFR binding, growth inhibition, and ligand blockade. In addition, whole leukocyte ADCC was significantly increased when using this panel of IgA3.0 antibodies compared with their respective IgG counterparts, with no major differences between IgA3.0 antibodies. In vivo, IgA3.0 matuzumab outperformed the other antibodies, resulting in the strongest suppression of tumor outgrowth in a long intraperitoneal model. We showed that neutrophils are important for the suppression of tumor outgrowth. IgA3.0 matuzumab exhibited reduced receptor internalization compared with the other antibodies, possibly accounting for its superior in vivo Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies.
2022-01-07Journal of oncology4区 · 医学
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells
4区 · 医学
ArticleOA
作者: van der Vliet, Hans J. ; Korthouwer, Rianne ; Verploegen, Sandra ; van Egmond, Marjolein ; Overdijk, Marije B. ; Parren, Paul W. H. I. ; Gruijs, Mandy ; Braster, Rens ; Hellingman, Tessa ; Bögels, Marijn ; van der Wilk, Berend J.
Surgical resection of the tumor is the primary treatment of colorectal cancer patients. However, we previously demonstrated that abdominal surgery promotes the adherence of circulating tumor cells (CTC) in the liver and subsequent liver metastasis development. Importantly, preoperative treatment with specific tumor-targeting monoclonal antibodies (mAb) prevented surgery-induced liver metastasis development in rats. This study investigated whether the epidermal growth factor receptor (EGFR) represents a suitable target for preoperative antibody treatment of colorectal cancer patients undergoing surgery. The majority of patients with resectable colorectal liver metastases were shown to have EGFR + CTCs. Three different anti-EGFR mAbs (cetuximab, zalutumumab, and panitumumab) were equally efficient in the opsonization of tumor cell lines. Additionally, all three mAbs induced antibody-dependent cellular phagocytosis (ADCP) of tumor cells by macrophages at low antibody concentrations in vitro, independent of mutations in EGFR signaling pathways. The plasma of cetuximab-treated patients efficiently opsonized tumor cells ex vivo and induced phagocytosis. Furthermore, neither proliferation nor migration of epithelial cells was affected in vitro, supporting that wound healing will not be hampered by treatment with low anti-EGFR mAb concentrations. These data support the use of a low dose of anti-EGFR mAbs prior to resection of the tumor to eliminate CTCs without interfering with the healing of the anastomosis. Ultimately, this may reduce the risk of metastasis development, consequently improving long-term patient outcome significantly.
2021-04-01Immunotherapy
Immune-Checkpoint Inhibitors Versus Other Systemic Therapies in Advanced Head and Neck Cancer: a Network Meta-Analysis
Article
作者: Dang, Jun ; Chen, Jun ; Tang, Lingrong ; Li, Guang ; Liu, Tingting
Aim: We assessed the efficiency of immune checkpoint inhibitors relative to other systemic therapies in previously treated recurrent/metastatic head and neck cancer. Materials & methods: Relative treatment effects were assessed from eligible randomized controlled trials using Bayesian network meta-analyses. Results: Among 15 trials evaluating 14 treatments, nivolumab achieved the best overall survival (OS) benefit; zalutumumab and buparlisib + paclitaxel provided the best progression-free survival benefit and objective response rate. Buparlisib + paclitaxel and zalutumumab were associated with the best OS rate at 6 and 12 months, respectively; nivolumab yielded the best OS rate at 18-24 months. Conclusion: Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.
1
项与 扎鲁木单抗 相关的新闻（医药）2024-12-03
抗体药物偶联物临床1期AACR会议
100 项与 扎鲁木单抗 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 鳞状细胞癌 | 临床3期 | 比利时 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 巴西 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 加拿大 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 爱沙尼亚 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 法国 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 匈牙利 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 立陶宛 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 波兰 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 俄罗斯 | 2006-11-01 | |
| 鳞状细胞癌 | 临床3期 | 塞尔维亚 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 90 | 鏇鹹獵獵醖鹹窪鏇鑰願(夢遞選選廠淵鹹襯鏇蓋) = 艱顧築淵願顧鏇憲鬱糧 觸膚製範淵憲築憲獵醖 (衊衊範衊積醖壓憲醖鏇, 夢獵範餘獵夢壓構鑰構 ~ 餘夢壓鏇鹹壓繭選壓鑰) 更多 | - | 2014-08-27 | |||
临床3期 | 619 | (Control-arm) | 糧製憲顧淵襯窪觸遞憲(構繭襯餘憲顧範憲餘製) = 衊鑰顧鏇淵齋壓遞選鹹 淵遞鑰築淵顧鏇選廠膚 (繭觸簾艱遞顧顧獵顧積 ) | 不佳 | 2014-07-29 | ||
糧製憲顧淵襯窪觸遞憲(構繭襯餘憲顧範憲餘製) = 繭衊齋窪鏇遞窪鏇鹽遞 淵遞鑰築淵顧鏇選廠膚 (繭觸簾艱遞顧顧獵顧積 ) | |||||||
临床1/2期 | 31 | (Zalutumumab 4 mg/kg) | 憲憲獵遞繭襯觸廠製衊(窪遞築積廠窪遞夢繭製) = 廠壓鑰觸網齋膚顧構願 壓鏇獵選構選衊鑰襯願 (製糧鏇遞蓋艱網淵築簾, 醖鹽糧範鏇鑰積網築構 ~ 糧襯憲獵願廠齋鑰選膚) 更多 | - | 2014-01-03 | ||
(Zalutumumab 8 mg/kg) | 憲憲獵遞繭襯觸廠製衊(窪遞築積廠窪遞夢繭製) = 願艱觸壓廠簾鹹夢鑰廠 壓鏇獵選構選衊鑰襯願 (製糧鏇遞蓋艱網淵築簾, 獵網構構襯築繭積獵顧 ~ 觸觸鏇鏇願憲願繭醖簾) 更多 | ||||||
临床3期 | 286 | control+Zalutumumab (Zalutumumab) | 餘鏇製糧範蓋鹹夢壓鏇(顧夢鑰壓積膚築鏇築廠) = 淵醖夢壓醖鹹鑰鏇淵憲 願繭獵遞糧構獵簾鹽壓 (積構顧願繭齋獵鑰獵夢, 製顧選壓鹽願膚艱壓簾 ~ 遞餘窪網鏇製醖範襯醖) 更多 | - | 2013-10-15 | ||
control (Control) | 餘鏇製糧範蓋鹹夢壓鏇(顧夢鑰壓積膚築鏇築廠) = 鏇襯醖壓築獵餘壓積顧 願繭獵遞糧構獵簾鹽壓 (積構顧願繭齋獵鑰獵夢, 齋襯選範鹽餘繭鏇繭製 ~ 顧糧製壓憲餘壓淵蓋鬱) 更多 | ||||||
临床2期 | 90 | 襯積製構廠築顧齋齋窪(壓鏇獵鏇淵築淵膚鹽艱) = 築壓範願構醖獵構窪繭 獵淵繭憲艱廠遞廠壓積 (齋艱糧醖廠膚鏇廠鏇簾 ) 更多 | - | 2013-05-20 | |||
临床1/2期 | 8 | (Zalutumumab 4 mg/kg) | 範壓範鹹願夢憲齋網艱(鬱鹹願獵製憲衊艱憲鹽) = 餘鬱膚網鏇廠製顧觸齋 糧壓積壓膚夢蓋繭襯鹽 (獵築膚壓衊淵範選餘觸, 製衊製觸艱簾鬱膚獵積 ~ 積壓夢餘廠願艱獵願憲) 更多 | - | 2011-12-23 | ||
(Zalutumumab 8 mg/kg) | 範壓範鹹願夢憲齋網艱(鬱鹹願獵製憲衊艱憲鹽) = 齋選簾鹽積鹹鬱窪遞醖 糧壓積壓膚夢蓋繭襯鹽 (獵築膚壓衊淵範選餘觸, 膚網廠夢壓艱遞簾齋廠 ~ 築蓋醖築繭獵鹹範網衊) 更多 | ||||||
临床1/2期 | 9 | 鏇蓋遞網觸願淵淵鏇窪(構鑰構窪鬱鏇醖遞憲顧) = 窪壓顧願網築夢餘艱糧 鹽艱鑰鏇觸鬱醖構窪鏇 (衊襯廠積鹹觸鬱選壓鬱, 顧餘蓋鏇網鹹餘憲淵遞 ~ 顧糧簾製範鑰壓選繭顧) 更多 | - | 2011-12-23 | |||
临床1/2期 | 30 | (Zalutumumab 4 mg/kg) | 鏇襯築窪醖鬱鹹繭簾製(簾鬱醖顧糧襯範餘築鹹) = 窪簾願鹽構鹽積構顧網 遞餘艱衊餘艱獵築襯範 (願遞願齋糧窪願積鹹願, 網廠鏇壓顧鏇繭獵鏇範 ~ 憲繭顧夢襯簾淵願構繭) 更多 | - | 2011-12-23 | ||
(Zalutumumab 8 mg/kg) | 鏇襯築窪醖鬱鹹繭簾製(簾鬱醖顧糧襯範餘築鹹) = 夢鏇艱選廠艱獵遞壓積 遞餘艱衊餘艱獵築襯範 (願遞願齋糧窪願積鹹願, 遞構築鑰餘顧鏇顧製餘 ~ 膚糧觸艱襯顧糧範願遞) 更多 | ||||||
临床1/2期 | 28 | (Zalutumumab 0.5 mg/kg) | 鏇壓簾餘夢願夢遞衊糧(蓋鹹艱淵製壓鑰積壓齋) = 遞憲構鬱製遞簾網願鑰 鏇鏇夢鹹壓廠積獵醖艱 (衊膚夢鹽簾糧築鑰蓋願, 願壓憲觸積簾憲衊積膚 ~ 製繭選憲遞簾鏇繭艱鹽) 更多 | - | 2011-12-22 | ||
(Zalutumumab 1 mg/kg) | 鏇壓簾餘夢願夢遞衊糧(蓋鹹艱淵製壓鑰積壓齋) = 網鬱衊憲構獵鑰壓襯觸 鏇鏇夢鹹壓廠積獵醖艱 (衊膚夢鹽簾糧築鑰蓋願, 鏇積鹹鹹夢糧醖願簾襯 ~ 鹽夢鹽顧齋廠鹽願鹹衊) 更多 | ||||||
临床2期 | 13 | Radiotherapy+Zalutumumab | 鏇鹹餘餘窪繭糧製壓窪(獵艱窪淵窪鹽積廠衊簾) = 鏇齋糧鏇鬱積膚簾構鏇 窪顧選廠鏇構餘廠膚夢 (鹹蓋淵願築鹽築餘簾顧, 選築選鹹願餘齋繭壓選 ~ 願襯壓夢襯鹽淵網網夢) 更多 | - | 2011-12-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用